Monoclonal antibody-based therapeutics for leukemia

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) are a unique class of therapeutics with high antigen specificity and effector functions.
• Antibody-based therapy is an established treatment modality for various cancers.
• Five of the nine FDA-approved mAbs and immunoconjugates for oncological diseases target hematological malignancies.

Purpose of the Study:

• To discuss the general aspects and mechanisms of action of therapeutic monoclonal antibodies.
• To highlight the development of antibody-based therapies for leukemia treatment.

Main Methods:

• Review of FDA-approved monoclonal antibodies and immunoconjugates for oncological indications.
• Discussion of specific antibody therapies for hematological malignancies, including alemtuzumab, rituximab, and gemtuzumab ozogamicin.
• Overview of monoclonal antibodies in various stages of clinical development for antileukemia therapy.

Main Results:

• Monoclonal antibodies demonstrate significant efficacy in treating hematological malignancies.
• Several antibody therapies are approved for specific leukemias, such as B cell chronic lymphocytic leukemia and acute myelogenous leukemia.
• Numerous other monoclonal antibodies are under investigation for their potential in leukemia therapy.

Conclusions:

• Therapeutic monoclonal antibodies are a vital and growing component of cancer treatment, especially for leukemia.
• The specificity and effector mechanisms of mAbs contribute to their success in targeting cancer cells.
• Ongoing research and clinical development promise further advancements in antibody-based leukemia therapies.